Indoco Remedies

Indoco Remedies EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Indoco Remedies (INDOCO.NS) as of Nov 15, 2026 is 0.59 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -0.33 % — a change of -276.70% (higher).

EBIT/Assets

0.59 %

YoY

-276.70%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Indoco Remedies is 2026 0.59 % . Operating Income to Assets Ratio (EBIT/Assets) of Indoco Remedies was 2025 -0.33 % . It decreases by -276.70% higher compared to the previous year.

The Indoco Remedies EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
0.85 INR
Jan 1, 2020
4.87 INR
Jan 1, 2021
11.72 INR
Jan 1, 2022
16.65 INR
Jan 1, 2023
11.92 INR
Jan 1, 2024
8.15 INR
Jan 1, 2025
-0.33 INR
Jan 1, 2026
0.59 INR
The Indoco Remedies EBIT/Assets history
YEAREBIT/AssetsYoY
0.59 %-276.70%
-0.33 %-104.11%
8.15 %-31.62%
11.92 %-28.41%
16.65 %+42.08%
11.72 %+140.68%
4.87 %+473.77%
0.85 %-83.73%
5.21 %-34.64%
7.98 %-32.40%
11.80 %-16.48%
14.13 %+13.85%
12.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Indoco Remedies Stock analysis

What does Indoco Remedies do? Indoco Remedies Ltd. manufactures and markets formulations and active pharmaceutical ingredients, offering medicines across therapeutic categories like diabetology, respiratory, and women's health. Its product portfolio includes brands such as Cyclopam, Sensodent-K, Karvol Plus, and Rexidin M, targeting both domestic and international markets. The company serves healthcare providers and consumers through its extensive range of pharmaceutical products, with subsidiaries supporting its global operations. The firm's revenue streams derive from the sale of finished dosage forms and APIs, with key brands like Cital UTI and Kidodent catering to specific medical needs. International markets represent a significant segment, complementing domestic sales, while subsidiaries such as Indoco Remedies Czech sro and Indoco Remedies UK Limited facilitate regional distribution and market expansion. Products like Lignox A and Homide are positioned for niche therapeutic applications, driving demand among healthcare professionals and patients. Indoco Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indoco Remedies stock

Operating Income to Assets Ratio (EBIT/Assets) of Indoco Remedies is 0.59 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of Indoco Remedies changed from -0.33 % to 0.59 %, representing a -276.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Indoco Remedies since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Indoco Remedies with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Indoco Remedies

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Indoco Remedies